Ardelyx, Inc. (ARDX)

NASDAQ • Healthcare

$3.34

-$0.04 (-1.2%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$3.38

Day Range$3.29 - $3.4

Avg. Volume (3M)4.2M

Market Cap$825M

52 Week Range

$3.29$8.4

Next EarningsIn 25 daysOct 29, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$120.8M100%

Gross Profitminus cost of goods$115.1M95%

In plain terms: out of every $100 in revenue, Ardelyx, Inc. currently loses $14.

Fundamentals & Financials

Revenue (TTM)

$450.8M

Net Income (TTM)

-$55.7M

EPS (TTM)

-$0.23

ROA (TTM)

-9.67%

Current Ratio

3.34

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+38.5%Q3 2025-$0.08

+93.3%Q4 2025$0

0.0%Q1 2026$0.02

-15.4%Q2 2026-$0.15

-7.0%Q3 2026-$0.07

Oct 29

in 25 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -7.0%

Ardelyx missed consensus on both the top and bottom line in the second fiscal quarter of 2026, reported Aug. 6 based on preliminary results, as EPS of -$0.07 versus the -$0.07 estimate was marked down 7.0% and revenue of about $120.9 million came in 0.1% below the $121.0 million consensus. Revenue rose 23.8% from $97.7 million a year ago, with gross profit around $115.1 million and gross margin near 95%, while operating loss reached about $12.4 million on an operating margin of -10.3%. Net income was a loss of about $16.7 million, up 12.4% from a loss of $19.1 million a year ago, and operating cash flow was negative $38.6 million.

Next report — what to expect

Ardelyx, Inc. (ARDX) reports on October 29, 2026. Wall Street is looking for consensus EPS of -$0.03 on revenue of $129.2 million. For trailing context, revenue grew +23.8% year over year last quarter. Ardelyx has beaten EPS in 3 of 8 most recent quarters.

View full earnings history

About Ardelyx, Inc.

Ardelyx, Inc. is a NASDAQ-listed biotechnology company focused on gastrointestinal and cardiorenal conditions, with tenapanor as its marketed product and pipeline anchor. The company generated $407.3 million of revenue in FY2025. Ardelyx changed its name from Nteryx, Inc. and operates from Waltham, Massachusetts.

Name

Ardelyx, Inc.

CEO

Michael G. Raab

Website

www.ardelyx.com

Industry

Healthcare

Year Founded

2007

Employees

489

Today's Snapshot

AI-generated

ARDX closed 1.2% lower at 3.34, while its sector was flat. ARDX closed within 1.5% of its 52-week low of 3.29. SBS Law, a securities law firm, invited investors to lead a securities-fraud lawsuit against Ardelyx.

Trading Volume

Above 10d avg 3.9M

vs S&P 500 Today

Underperforming Market

-1.96%

Updated: October 2, 2026 at 20:21 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

ARDX is exhibiting broad technical weakness: the ADX shows a strong directional trend while momentum measures are subdued, with RSI hovering near the low 30s and MACD slightly negative, indicating limited bullish momentum. The stock trades well below most moving averages, including the 200-day level, and on-balance volume is markedly negative, reinforcing distribution. Volatility is moderate by average true range and the price sits near the lower Bollinger Band and just under the classic pivot, which suggests recent selling pressure has compressed trading range. Technical takeaway: Strong Sell based on persistent downtrend, weak momentum and negative volume.

All signals